TScan Therapeutics (TCRX) Total Debt (2022 - 2026)
TScan Therapeutics (TCRX) posted quarterly Total Debt of $32.7 million for Q1 2026, up 1.47% year-over-year from $32.2 million in Q1 2025, and little changed quarter-over-quarter from $32.5 million in Q4 2025.
TScan Therapeutics (TCRX) Total Debt (2022 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Total Debt for 5 consecutive years, with $32.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 1.47% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at $32.7 million (up 1.47% YoY), while the FY2025 annual figure was $32.5 million, up 1.44% from the prior year.
- Total Debt was little changed at $32.7 million in Q1 2026 per TCRX's latest filing, from $32.5 million in the prior quarter.
- Across five years, Total Debt topped out at $32.7 million in Q1 2026 and bottomed at $29.1 million in Q3 2022.
- Historically, Total Debt has averaged $30.9 million across 5 years, with a median of $30.4 million in 2024.
- Annual changes were most pronounced in 2024 — Total Debt climbed 6.74% — and 2025, when it grew 1.44%.
- TScan Therapeutics' Total Debt stood at $29.3 million in 2022, then rose by 2.58% to $30.0 million in 2023, then increased by 6.74% to $32.1 million in 2024, then increased by 1.44% to $32.5 million in 2025, then increased by 0.37% to $32.7 million in 2026.
- Business Quant data shows TCRX's Total Debt at $32.7 million in Q1 2026, $32.5 million in Q4 2025, and $32.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.34 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 32.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.78 Mn |
| Mar 31, 2026 | 32.65 Mn |
| Dec 31, 2025 | 32.53 Mn |
| Sep 30, 2025 | 32.41 Mn |
| Jun 30, 2025 | 32.30 Mn |
| Mar 31, 2025 | 32.18 Mn |
| Dec 31, 2024 | 32.07 Mn |
| Sep 30, 2024 | 30.65 Mn |
| Jun 30, 2024 | 30.45 Mn |
| Mar 31, 2024 | 30.25 Mn |
| Dec 31, 2023 | 30.05 Mn |
| Sep 30, 2023 | 29.95 Mn |
| Jun 30, 2023 | 29.72 Mn |
| Mar 31, 2023 | 29.50 Mn |
| Dec 31, 2022 | 29.29 Mn |
| Sep 30, 2022 | 29.07 Mn |